NEWAVX is thrilled to announce that it has been awarded a £150,000 grant through the West Midlands Health Tech Innovation Accelerator (WMHTIA). This funding will enable NEWAVX to collaborate with the University of Birmingham on groundbreaking research into Vortex Wave Circulation therapy (VWC), a critical step toward addressing some of the most pressing unmet health needs in the UK.

The WMHTIA initiative, funded by the Department for Science, Innovation and Technology in partnership with Innovate UK and the West Midlands Combined Authority, aims to foster innovation in health technology across the region. This grant recognises the potential of NEWAVX’s pioneering research, which is supported by independent, clinically peer-reviewed evidence, and underscores our commitment to enhancing healthcare solutions in a post-COVID landscape.

CEO and Co-Founder Francesca Fox expressed her enthusiasm: “I am delighted to know that the independent, clinically peer-reviewed evidence supporting our Vortex Wave Circulation therapy (VWC) has been instrumental in bringing our innovation to market, specifically designed to address severe and unmet health needs across the UK. Since the onset of COVID, we have worked tirelessly alongside our research partners from the University of Birmingham, Birmingham City University, and Cambridge University. Together, we are committed to ensuring that VWC therapy reaches those who need it most.”

NEWAVX is dedicated to transforming healthcare through innovative therapies and is committed to making a positive impact on the health and well-being of communities across the UK.
For media inquiries, please contact: Francesca@newavx.health

Full press release: https://wmhtia.com/wmhtia-grant-funding-to-empower-innovators-driving-their-health-technologies-forward/?fbclid=IwY2xjawFCXlxleHRuA2FlbQIxMAABHaFHcrY4YxtGRX816F5ZlIqvcpdnFeqOrSXXPngUhZIg3MsYy009-qDCdQ_aem_PpLjnN9Rkr5vxdz8uPfdAA

About NEWAVX:

NEWAVX is an emerging leader in developing cutting-edge health technologies focused on addressing unmet healthcare needs. As a startup, we harness advanced artificial intelligence and proprietary technologies to drive innovation within the NHS. Our solutions are designed to create personalised treatment plans and utilise predictive analytics, targeting the root causes of chronic conditions such as diabetes.

We are committed to delivering proactive solutions for age-related health challenges, including sarcopenia, osteoporosis, and dementia. Our innovative physiotherapy tool is specifically tailored for athletes, enhancing performance and promoting optimal recovery.

With a strong emphasis on research and collaboration, NEWAVX is dedicated to pioneering transformative healthcare solutions that significantly improve patient outcomes and redefine the standards of care in the healthcare landscape.